Zealand Pharma A's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Zealand Pharma A (ZEAL) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Zealand Pharma A vs Its Competitors
- TTM: Trailing 12-month revenue of 47M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.1% annualized vs trailing 12 months).
- Peer revenue share: Zealand Pharma A accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
ZEAL Sales vs. its Competitors, Q4 2021
Zealand Pharma A generated 100.00 % of the combined sales of its peer group.
Zealand Pharma A's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Zealand Pharma A | - | No | No | No |
| Competitors combined (1) | - | - | - | |
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
ZEAL Stock Performance relative to its Competitors
ZEAL Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Skye Bioscience Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Zealand Pharma A's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Zealand Pharma A
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Zealand Pharma A |
754.07 | 46.54 |
 Skye Bioscience Inc |
7.19 | - |
| SUBTOTAL | 761.27 | 46.54 |
Sources: Zealand Pharma A's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Zealand Pharma A versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Zealand Pharma A's Competitors Named by the Company
Competitive relationships identified from Zealand Pharma A reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Skye Bioscience Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Ironwood Pharmaceuticals inc | Company report | 85% |
| Terns Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Zealand Pharma A's named competitors require a Commercial License.
Methodology: relationships are extracted from Zealand Pharma A reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Zealand Pharma A's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Zealand Pharma A | 754 | 119,337 | -415,300 |
| Skye Bioscience Inc | 7 | - | -4,777,571 |
| PEERS TOTAL | 7 | - | -4,777,571 |
Zealand Pharma A's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue Growth | 2.92 % | 500.00 % | -13.95 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -22.16 % | -27.99 % | -19.89 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Zealand Pharma A's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 7.57 % vs industry average 7.06 % (see Profitability & Cost Structure above) |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments. Supplier power and buyer power are not assessed here -- see Zealand Pharma A's dedicated Suppliers and Customers pages for concentration data; threat of substitutes has no systematic data source in this system and is not estimated.
Zealand Pharma A's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+300.1% annualized vs trailing 12 months).
Weaknesses
- Return on equity 136.3 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Zealand Pharma A's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Zealand Pharma A | 3.38 | 5.15 | 0.84 |
| Skye Bioscience Inc | 1.60 | 3.86 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Zealand Pharma A's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Zealand Pharma A | Q4 2021 | -13.9 % | - |
| Skye Bioscience Inc | Q1 2026 | - | - |
| PEERS TOTAL | -13.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Zealand Pharma A's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Zealand Pharma A | Q4 2021 | +389.6 % | -8.2 % |
| Skye Bioscience Inc | Q1 2026 | - | - |
Zealand Pharma A's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Zealand Pharma A | - | - | - |
| Skye Bioscience Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Zealand Pharma A's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Zealand Pharma A | - | 16.20 |
| Skye Bioscience Inc | - | - |
| PEERS AVERAGE | - | 16.36 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.